Deal Watch: Merck Hopes Moderna's Personalized Vaccines Can Increase Keytruda Patient Base

Novartis and Xencor sign wide-ranging immuno-oncology collaboration targeting multiple CD pathways. Teva signs divestment agreements with five firms during June to meet FTC requirements for its acquisition of Allergan's generics business.